In a nutshell This study evaluated the effectiveness of daratumumab (Darzalex)-containing regimens in patients with multiple myeloma (MM) unresponsive to lenalidomide (Revlimid) maintenance therapy. The data showed that daratumumab-containing therapies are effective regimens in these patients. Some background Multiple myeloma (MM) is a type...
Read MoreCurrent disease status-First occurrence of the myeloma Posts on Medivizor
Evaluating the effectiveness and safety of an all-oral combination of ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma undergoing stem cell transplantation.
In a nutshell This study evaluated the effectiveness and safety of an all-oral combination of ixazomib (Ninlaro), lenalidomide (Revlimid), and dexamethasone (Decadron) in transplant-eligible patients with newly diagnosed multiple myeloma (MM). The data showed that this combination was effective with manageable side effects in these...
Read MoreAdding daratumumab to lenalidomide and dexamethasone therapy for the treatment of patients with newly diagnosed multiple myeloma.
In a nutshell This study evaluated the effectiveness and safety of adding daratumumab (Darzalex) to lenalidomide (Revlimid) and dexamethasone (Decadron) therapy for patients with newly diagnosed multiple myeloma (MM). The data showed that adding daratumumab to the lenalidomide and dexamethasone (Rd) regimen was safe and improved...
Read MoreEffectiveness of VCD-VTD therapy for older patients with newly diagnosed multiple myeloma.
In a nutshell This study assessed the effects of administering personalized doses of VCD (bortezomib, cyclophosphamide, and dexamethasone) followed by VTD (bortezomib, thalidomide, and dexamethasone) in older patients with newly diagnosed multiple myeloma (NDMM). The data showed high response rates and safety in these patients. Some background...
Read MoreEvaluating long-term outcomes of autologous SCT for patients with recurrent multiple myeloma
In a nutshell This study evaluated the outcomes of autologous stem cell transplantation (ASCT) for patients with recurrent multiple myeloma (MM). This study found that long-term outcomes for these patients were promising, especially for patients who had the transplant right away after a first relapse. Some background Multiple myeloma (MM) is a type of...
Read MoreIs autologous stem cell transplant safe and effective for patients aged 75 or older with multiple myeloma?
In a nutshell The aim of this study was to evaluate the safety and effectiveness of autologous stem cell transplant (ASCT) in patients with multiple myeloma (MM) aged 75 or older. The study found that ASCT was safe and effective for certain patients in this age group. Some background MM is a type of blood cancer that impacts bone marrow. Therapy for...
Read MoreEvaluating carflizomib, lenalidomide, dexamethasone, and cyclophosphamide for newly diagnosed transplant-eligible patients with multiple myeloma.
In a nutshell This study compared a combination therapy of carfilzomib (Kyprolis), lenalidomide (Revlimid), dexamethasone (Decadron), and cyclophosphamide (Cytoxan) to control combination therapies as an alternative treatment regimen in newly diagnosed patients with multiple myeloma (MM). The authors concluded that this regimen provided very good...
Read MoreLong-term follow-up after bortezomib, thalidomide, and dexamethasone treatment followed by double stem cell transplant in patients with multiple myeloma.
In a nutshell This study compared long-term outcomes after treatment with bortezomib (Velcade), thalidomide (Thalomid), and dexamethasone (Ozurdex) or VTD compared to thalidomide and dexamethasone (TD) followed by double hematopoietic stem cell transplant (HSCT) in patients with newly diagnosed multiple myeloma (MM). The study found...
Read MoreWhen should stem-cell transplants be given during multiple myeloma treatment?
In a nutshell This study was carried out to determine whether early stem cell transplant (SCT) or a delayed SCT improved the survival of patients with multiple myeloma (MM). The study found that there was no significant difference in survival in patients with newly diagnosed MM who received early or late SCT. Some background SCT is an...
Read MoreElotuzumab, lanalidomide and dexamethasone increases overall survival of patients with relapsed or refractory multiple myeloma.
In a nutshell This trial was carried out to examine the effectiveness and safety of elotuzumab (Empliciti), lenalidomide (Revlimid), and dexamethasone (Decadron) in relapsed or refractory (unresponsive) multiple myeloma (MM). The authors found that there was an improved survival in these patients in the long-term. Some...
Read MoreShould maintenance therapy be used in transplant ineligible adults with multiple myeloma?
In a nutshell This article was carried out to analyze trials carried out in order to assess the role of maintenance therapy in transplant-ineligible (TI) patients with multiple myeloma (MM) following induction therapy. The authors found that maintenance therapy increases survival without disease worsening in these patients. Some background MM is...
Read MoreCan the addition of bortezomib improve treatment results long-term for patients with multiple myeloma?
In a nutshell This study examined if the addition of bortezomib (Velcade) to treatment with lenalidomide (Revlimid) and dexamethasone (Decadron) could improve treatment results long-term for patients with multiple myeloma (MM). The authors found that patients who received bortezomib had a longer survival long-term. Some background...
Read More